Johnson & Johnson's Varipulse PFA System Receives FDA Approval for Atrial Fibrillation Treatment
核心洞察
Johnson & Johnson MedTech's Varipulse (搜索) pulsed field ablation (PFA) platform has been approved by the FDA for treating atrial fibrillation (搜索) (AFib (搜索)).
The Varipulse (搜索) system integrates PFA technology with the Carto 3 mapping system, offering real-time visualization and feedback during ablation procedures.
Approval was based on the adMIRE study, which demonstrated the safety and efficacy of Varipulse (搜索) in AFib (搜索) treatment, providing a new option for nearly eight million Americans affected by AFib.
Johnson & Johnson MedTech has secured FDA approval for its Varipulse (搜索) pulsed field ablation (PFA) platform, marking a significant advancement in the treatment of atrial fibrillation (搜索) (AFib (搜索)). This approval positions Johnson & Johnson alongside Medtronic and Boston Scientific as providers of PFA technologies for AFib, a condition affecting nearly eight million people in the U.S.
The Varipulse (搜索) system uniquely combines PFA with the Carto 3 mapping system, offering electrophysiologists an integrated solution for AFib (搜索) ablation. The platform includes the variable-loop, multielectrode Varipulse catheter, the TruPulse generator, and the Carto 3 3D cardiac mapping system. According to Johnson & Johnson’s Biosense Webster, the Carto integration facilitates an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.
The key feature of the Varipulse (搜索) platform is its ability to deliver precise energy, enhancing accuracy and safety during ablation procedures. The system also supports minimal-to-zero fluoroscopy workflows through integration with intracardiac echocardiography (ICE) ultrasound, reducing radiation exposure for patients and healthcare providers.
Clinical Evidence
The FDA approval was supported by data from the adMIRE study, which demonstrated the safety and efficacy of the Varipulse (搜索) platform. The study highlighted the platform's potential to provide effective AFib (搜索) treatment with a favorable safety profile.
Expert Commentary
"With this approval, we are excited to bring the Varipulse (搜索) Platform to electrophysiologists and patients in the U.S., where AFib (搜索) impacts nearly eight million people," said Jasmina Brooks, President of Johnson & Johnson MedTech Electrophysiology. "As the only PFA platform uniquely designed for seamless integration with the Carto 3 System, we are confident that this eagerly awaited platform will be a valuable tool for physicians in performing safe, effective and efficient AFib procedures with an intuitive and reproducible workflow, and minimal-to-no fluoroscopy."
The Varipulse (搜索) PFA system represents a significant step forward in AFib (搜索) treatment, offering an innovative approach that combines precision, safety, and efficiency. Its integration with the Carto 3 system and minimal fluoroscopy capabilities position it as a valuable tool for electrophysiologists seeking to improve patient outcomes in AFib ablation procedures.